Betta Pharmaceuticals Partner's Phase 3 Trials for Retinal Disease Treatment Fail Pre-Specified Primary Endpoint

MT Newswires Live10-20

Betta Pharmaceuticals' (SHE:300558) partner EyePoint said phase 3 clinical trials evaluating the Duravyu product did not meet a pre-specified primary endpoint, according to a Tuesday filing with the Shenzhen bourse.

Duravyu is a vorolanib intravitreal insert is indicated for patients with serious retinal diseases.

The drug missed the primary endpoint of statistical non-inferiority in mean change in best corrected visual acuity during the trial despite meeting the endpoints in the first two trials, the filing said.

Betta Pharmaceuticals' subsidiary Equinox granted EyePoint a license to use vorolanib, an ingredient in Duravyu, to treat ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan, EyePoint said in a separate news release.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment